Navigation Menu

Clinical Trial External Search


Children (age < 18 years)
Adults (age >= 18 years)

Thoracic Cancer Research

Clinical Trial Disease Team

Research Thoracic Cancer Overview

Research into thoracic cancer at Penn State Cancer Institute is conducted by our dedicated thoracic cancer team. See current clinical trials and members of that team here.

Clinical Trials

Repository of Lung Cancer Diagnostic Procedure Images
Piloting a Virtual Navigation (VN) System for Bronchoscopic Tissue Sampling
Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
The COVID-19 and Cancer Consortium (CCC19) Registry
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
A Phase II, Multicenter, Randomized, Open-Label Trial of GEN1046 as monotherapy and in Combination with Anti-cancer Therapy in Subjects with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer who failed first-line Standard of Care therapy with an Immune Checkpoint Inhibitor
S1914 A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
Adapting an Advance Care Planning Intervention and Delivery model for Use with Patients with Advanced Cancer and their Caregivers
General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease
Oncogenic Mutations/Gene Rearrangements in Patients with Advanced Adenocarcinoma Lung
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer

Disease Team Members

First Name Last Name Title Role
Chandra Belani, MD Chandra Belani MD
Mitchell Machtay, MD Mitchell Machtay MD
Rickhesvar Mahraj, MD, FRCP, FRCR Rickhesvar Mahraj MD, FRCP, FRCR
Michael F. Reed, MD Michael F. Reed MD
Matthew D. Taylor, MD Matthew D. Taylor MD
Jennifer Toth, MD Jennifer Toth MD
Leonard Tuanquin, MD Leonard Tuanquin MD

Research Thoracic Cancer Overview

Research into thoracic cancer at Penn State Cancer Institute is conducted by our dedicated thoracic cancer team. See current clinical trials and members of that team here.
Repository of Lung Cancer Diagnostic Procedure Images
Piloting a Virtual Navigation (VN) System for Bronchoscopic Tissue Sampling
Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
The COVID-19 and Cancer Consortium (CCC19) Registry
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
A Phase II, Multicenter, Randomized, Open-Label Trial of GEN1046 as monotherapy and in Combination with Anti-cancer Therapy in Subjects with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer who failed first-line Standard of Care therapy with an Immune Checkpoint Inhibitor
S1914 A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
Adapting an Advance Care Planning Intervention and Delivery model for Use with Patients with Advanced Cancer and their Caregivers
General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease
Oncogenic Mutations/Gene Rearrangements in Patients with Advanced Adenocarcinoma Lung
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer
First Name Last Name Title Role
Chandra Belani, MD Chandra Belani MD
Mitchell Machtay, MD Mitchell Machtay MD
Rickhesvar Mahraj, MD, FRCP, FRCR Rickhesvar Mahraj MD, FRCP, FRCR
Michael F. Reed, MD Michael F. Reed MD
Matthew D. Taylor, MD Matthew D. Taylor MD
Jennifer Toth, MD Jennifer Toth MD
Leonard Tuanquin, MD Leonard Tuanquin MD